MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...